



Breast Cervical & Colon Health Program 401 5th Ave #1110 Seattle WA 98104 T 206-263-8176 F 206-296-0208

Breast, Cervical and Colon Health Program Saving Lives Through Early Detection

Prior Authorization Form

BCCHP requires prior authorization for MRI, LEEP, and Cervical Conization. Each case will be reviewed by the prime contractor in collaboration with the BCCHP Nurse Consultant and at times the Medical Advisory Committee (MAC). Please refer to the BCCHP fee schedule for reimbursement. BCCHP follows ASCCP guidelines for cervical cases.

Client Name (Last, First, MI)		BCCHP#:		Authorization #:			
		Date of Birth	Last	four SS # (optional)	Chart Nu	umber	
		Referring Provider Name	Plac	e of Service	Date of r	procedure	
					Date of	procedure	
		On a sight Drey idea Name		Office 🔲 Hospital			
Specialty Clinic Site Specia		Specialty Provider Name		ASC			
	Cervical Procedures						
Cervical Procedure Requests	Colposcopy with LEEP Biopsy (57460)						
	Colposcopy with LEEP electrode conization (57461)						
				Results (For LEEP approval, ECC or biopsy results must			
	Pap Results	HPV Results					
	ASC-US ASC-H	HPV High Risk Testing	be CIN 2 or higher, see ASCCP guidelines)				
		Pos 🗌 Neg 🗌					
Ce	AGC	HPV 16 & 18 genotyping	Cervical Biopsy	CIN 2 CIN 3			
		Pos 🗌 Neg 🗌					
	Breast Procedures						
Breast Procedure Requests	Diagnostic Breast MRI						
	MRI guided breast biopsy with placement of localization device (19085, 19086)						
	MRI guided placement of breast localization device (19287, 19288)						
	Breast Screening MRI unilateral (77046 without contrast, 77048 includes CAD w/ or w/o contrast) (only for high risk)						
	Breast Screening MRI bilateral (77047 without contrast, 77049 includes CAD w/ or w/o contrast) (only for high risk)						
	MRI should never be used alone as a screening tool. MRI should not be used as a diagnostic tool for a palpable mass.						
	BCCHP does not reimburse for MRI to determine extent of disease in a woman already diagnosed with breast cancer.						
	CBE and Imaging Results (<i>include report</i>)						
	□ Palpable mass						
	Mammogram finding:						
	Ultrasound finding:						
rre	MRI finding: Suspicious Indeterminate						
edi	MRI guided biopsy and/or localization only approved when there is no sonographic evidence of the abnormality.						
ast Proc	Breast Cancer Risk: Approval for screening MRI requires patient be assessed as high-risk for breast cancer.						
	Risk assessment models approved by BCCHP include: Tyrer-Cuzick, BRCAPRO, Claus and BOADICEA. The Gail Model is not accepted by BCCHP. Was the Tyrer-Cuzick (IBIS) model used?YesNo						
Brea	If so, Lifetime Risk:% (20% or higher is considered high risk)						
-							
	If a different tool was used please list tool and result						
	Screening contexts that do not require the use of an assessment tool (please check if applicable and provide notes):						
	Chest wall radiation before the age of 30 Positive for BRCA mutation, or first-degree relative with BRCA mutation						
	Positive for BRCA induction, or inscrete relative with BRCA induction History of genetic pre-disposition (e.g. Li-Fraumeni, Cowden, or Bannayan-Riley-Ruvalcaba syndromes)						
	Does the client have a history of breast cancer?YesNo						
	Note: For clients with a history of breast cancer, BCCHP follows the recommendation of the oncologist or breast surgeon. Please provide chart notes						
	with clinical recommendations. If specialist information is unavailable, communicate with prime contractor.						
	BCCHP does not cover or reimburse for genetic testing, genetic counseling, or breast cancer treatment.						
Provider Comments:							
Provider Signature:		Print Name:	Print Name:		mber:	Date:	
						July.	
		Not Approved Deserved	D-4				
BCCHP Prime Contractor Use Only Approved Not Approved Reason Date:							